Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
212.74
+2.61 (+1.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
↗
May 12, 2025
Via
The Motley Fool
3 Monster Stocks in the Making
↗
May 11, 2025
Via
The Motley Fool
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
↗
May 05, 2025
Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.
Via
Benzinga
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
↗
February 27, 2025
Via
Benzinga
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
May 01, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
↗
April 29, 2025
Via
Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
April 22, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)
April 14, 2025
From
Grabar Law Office
Via
GlobeNewswire
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates
April 11, 2025
From
Grabar Law Office
Via
GlobeNewswire
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
April 08, 2025
From
Grabar Law Office
Via
GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
April 08, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
April 07, 2025
Via
Benzinga
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
April 07, 2025
From
Grabar Law Office
Via
GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions
April 04, 2025
From
Grabar Law Office
Via
GlobeNewswire
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
April 04, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Stocks Edge Higher Despite Trade, Economic Jitters
↗
April 01, 2025
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data.
Via
Talk Markets
Topics
Stocks / Equities
Why Shares of Axsome Therapeutics Slumped Today
↗
April 01, 2025
Via
The Motley Fool
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
↗
April 01, 2025
The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group.
Via
Investor's Business Daily
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder
↗
April 01, 2025
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025.
Via
Benzinga
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
April 01, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
↗
March 27, 2025
Via
Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views
↗
March 27, 2025
Via
Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
↗
March 25, 2025
Via
The Motley Fool
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
↗
March 25, 2025
The company is working on a non-stimulant approach to treating ADHD.
Via
Investor's Business Daily
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
↗
March 25, 2025
Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile.
Via
Benzinga
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
March 25, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
March 05, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
March 03, 2025
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
